NO20003804L - FremgangsmÕte for fremstilling av absorberbare mikropartikler - Google Patents

FremgangsmÕte for fremstilling av absorberbare mikropartikler

Info

Publication number
NO20003804L
NO20003804L NO20003804A NO20003804A NO20003804L NO 20003804 L NO20003804 L NO 20003804L NO 20003804 A NO20003804 A NO 20003804A NO 20003804 A NO20003804 A NO 20003804A NO 20003804 L NO20003804 L NO 20003804L
Authority
NO
Norway
Prior art keywords
microparticles
making absorbable
microparticle
bound
absorbable microparticles
Prior art date
Application number
NO20003804A
Other languages
English (en)
Other versions
NO20003804D0 (no
Inventor
Thomas Ciaran Loughman
Original Assignee
Kinerton Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kinerton Ltd filed Critical Kinerton Ltd
Publication of NO20003804D0 publication Critical patent/NO20003804D0/no
Publication of NO20003804L publication Critical patent/NO20003804L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Denne oppfinnelsen vedrører en fremgangsmåte for å fremstille en omsluttet bundet mikft^-opartikkel vedvarende frigivelseskompleks som omfatter en eller flere peptider, en eller flere proteiner eller en kombinasjon derav immobilisert på en absorberbar po- lymermikropartikkel som har et absorberbart polymerbelegg, hvor nevnte fremgangs- måte omfatter forstøvning av en dispersjon av de bundede mikropartiklene.
NO20003804A 1998-01-29 2000-07-25 FremgangsmÕte for fremstilling av absorberbare mikropartikler NO20003804L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE980054 1998-01-29
PCT/IE1999/000007 WO1999038535A1 (en) 1998-01-29 1999-01-25 Process for making absorbable microparticles

Publications (2)

Publication Number Publication Date
NO20003804D0 NO20003804D0 (no) 2000-07-25
NO20003804L true NO20003804L (no) 2000-09-20

Family

ID=11041696

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003804A NO20003804L (no) 1998-01-29 2000-07-25 FremgangsmÕte for fremstilling av absorberbare mikropartikler

Country Status (17)

Country Link
US (1) US6555156B1 (no)
EP (1) EP1051194B9 (no)
JP (1) JP2002501907A (no)
CN (1) CN1289255A (no)
AR (1) AR014069A1 (no)
AT (1) ATE240121T1 (no)
AU (1) AU740493B2 (no)
CA (1) CA2318513A1 (no)
DE (1) DE69907870T2 (no)
DK (1) DK1051194T3 (no)
ES (1) ES2194437T3 (no)
HU (1) HUP0102373A2 (no)
IL (1) IL137349A0 (no)
NO (1) NO20003804L (no)
PL (1) PL342135A1 (no)
PT (1) PT1051194E (no)
WO (1) WO1999038535A1 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413539B1 (en) * 1996-10-31 2002-07-02 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
IES990700A2 (en) * 1999-08-18 2001-08-22 Kinerton Ltd Process to make a sustained release formulation
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US7229966B2 (en) 2002-12-17 2007-06-12 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7186692B2 (en) 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
BR0316685A (pt) 2002-12-17 2005-11-01 Nastech Pharm Co Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade
KR20070010115A (ko) * 2003-11-13 2007-01-22 알자 코포레이션 경피전달용 조성물 및 장치
US7976847B2 (en) * 2004-01-13 2011-07-12 Vasogenix Pharmaceuticals, Inc. Controlled release CGRP delivery composition for cardiovascular and renal indications
JP2007517911A (ja) * 2004-01-13 2007-07-05 バソジェニックス ファーマシューティカルズ， インコーポレイテッド 心臓血管の適応症および腎臓の適応症に対してｃｇｒｐを使用する方法
EP1703916A2 (en) * 2004-01-13 2006-09-27 Vasogenix Pharmaceuticals, Inc. Methods for treating acute myocardial infarction by calcitonin gene related peptide and compositions containing the same
US7578951B2 (en) * 2004-01-27 2009-08-25 Hewlett-Packard Development Company, L.P. Method of making microcapsules utilizing a fluid ejector
CA2584670A1 (en) 2004-10-19 2006-04-27 Achillion Pharmaceuticals, Inc. Combination therapy for treating viral infections
FR2880272A1 (fr) * 2005-01-04 2006-07-07 Jean Marc Ruiz Preparation contenant des microparticules d'un sel de polymere insoluble portant un principe actif, ainsi que son procede de fabrication
DK2118123T3 (en) 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabilized p53 peptides and uses thereof
US8592377B2 (en) 2007-03-28 2013-11-26 President And Fellows Of Harvard College Stitched polypeptides
CA2730760A1 (en) * 2008-07-16 2010-01-21 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles containing bioactive peptides
US8968787B2 (en) * 2010-05-24 2015-03-03 Micro Powders, Inc. Composition comprising biodegradable polymers for use in a cosmetic composition
ES2711526T3 (es) 2010-08-13 2019-05-06 Aileron Therapeutics Inc Macrociclos peptidomiméticos
DE102011114864A1 (de) 2011-10-05 2013-04-11 Acino Ag Verfahren zur Herstellung einer homogenen Pulvermischung und Verfahren zur Herstellung eines Implantats sowie Implantat
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc TRIAZOL AND THIOETHER-COUPLED PEPTIDOMIMETIC MACROCYCLES
BR112014020103A2 (pt) 2012-02-15 2018-10-09 Aileron Therapeutics, Inc. macrociclos peptidomiméticos
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CA3004363A1 (en) 2015-11-06 2017-05-11 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Composition comprising a biocompatible and biodegradable polymer, nanocarries and a drug and methods of making and using the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US5385738A (en) 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
US5011692A (en) 1985-12-28 1991-04-30 Sumitomo Pharmaceuticals Company, Limited Sustained pulsewise release pharmaceutical preparation
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5077049A (en) 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
AU653771B2 (en) * 1991-01-03 1994-10-13 Alkermes Controlled Therapeutics, Inc. Stabilization of proteins by cationic biopolymers
US5366756A (en) 1992-06-15 1994-11-22 United States Surgical Corporation Method for treating bioabsorbable implant material
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
CA2167920A1 (en) * 1993-07-23 1995-02-02 Abraham J. Domb Nonoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5612052A (en) 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5874029A (en) * 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US6270700B1 (en) * 1998-07-23 2001-08-07 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Encapsulation of water soluble peptides

Also Published As

Publication number Publication date
NO20003804D0 (no) 2000-07-25
WO1999038535A1 (en) 1999-08-05
US6555156B1 (en) 2003-04-29
CA2318513A1 (en) 1999-08-05
IL137349A0 (en) 2001-07-24
DK1051194T3 (da) 2003-09-01
PL342135A1 (en) 2001-05-21
HUP0102373A2 (hu) 2001-10-28
AU2296699A (en) 1999-08-16
AU740493B2 (en) 2001-11-08
AR014069A1 (es) 2001-01-31
EP1051194B9 (en) 2003-11-05
DE69907870D1 (de) 2003-06-18
DE69907870T2 (de) 2004-03-04
PT1051194E (pt) 2003-09-30
ES2194437T3 (es) 2003-11-16
ATE240121T1 (de) 2003-05-15
JP2002501907A (ja) 2002-01-22
CN1289255A (zh) 2001-03-28
EP1051194A1 (en) 2000-11-15
EP1051194B1 (en) 2003-05-14

Similar Documents

Publication Publication Date Title
NO20003804L (no) FremgangsmÕte for fremstilling av absorberbare mikropartikler
EP1697511A4 (en) IMMUNOTHERAPY COMPOSITIONS, METHOD OF PREPARATION AND METHOD FOR USE THEREOF
LUC00074I2 (en) Method for controlling the activity of immunologically functional molecule
EP1526454A3 (en) Application identity for software products
EP1637961A3 (en) Deploying and receiving software over a network susceptible to malicious communication
DE69935547D1 (de) Mit Vertiefungen versehner, optischer Verteiler für Fahrzeug-Beleuchtungssystem
PT805822E (pt) Eritropoietina seca por pulverizacao
ATE308893T1 (de) Beschichtungsanlage für gegebenenfalls marmorierte konditorwaren
CA2383926A1 (en) Functional genomics using zinc finger proteins
ATE308114T1 (de) Verfahren und vorrichtung zur clusterfragmentation
DE60034566D1 (de) Peptidakzeptor ligationsverfahren
WO2006138379A3 (en) Resolving resource allocation conflicts for access terminals
DE59811911D1 (de) Verfahren zur Herstellung von stabilen, feinteiligen Polymerdispersionen
BR0016261B1 (pt) método para preparação de um acelerador para concreto de pulverização.
CA2320224A1 (en) Method for modulating macrophage activation
AU1384199A (en) Method for producing igf-1 sustained-release formulations
WO2001032877A3 (en) CpG RECEPTOR (CpG-R) AND METHODS RELATING THERETO
AU1091899A (en) Methods of making a molecular sieve containing catalyst
DE50001295D1 (de) Imidochromverbindungen in katalysatorsystemen für die olefinpolymerisation
WO2001000875A3 (en) Novel methods and products for arrayed microsphere analysis
DE69819949D1 (de) Verfahren zur Herstellung von Polyethylen-2,6-Naphthalendicarboxylat-Harz.
BR9609961A (pt) Dispositivo para o desprendimento da ancoragem de um pedal da estrutura de um veículo automotivo
BRPI9808642B8 (pt) processo para preparar eprosartan a partir de 2-n-butil-4-formilidazol
WO2002076032A3 (de) Verfahren und vorrichtung zur erstellung eines zeitplans der übermittlung von nachrichten auf einem bussystem
NO960510L (no) Fremgangsmåte for å fremstille små, diskrete, sfæriske addukter

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application